← Back to Search

Other

Arm 1: Healthy Japanese Participants for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by AbbVie

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 45 days

Awards & highlights

Study Summary

This trial will assess safety and how ABBV-552 moves through the body of 18 adult healthy Japanese & Han Chinese volunteers. Adverse Events will be monitored.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 45 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 45 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 45 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

AUC From Time Zero to Infinite Time (AUCinf) of ABBV-552

AUC of ABBV-552 (Arm 1)

Apparent Oral Clearance (CL/F) of ABBV-552

+8 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm 2: Healthy Han Chinese ParticipantsExperimental Treatment1 Intervention

Participants will receive ABBV-552 once a week for 7 Days.

Group II: Arm 1: Healthy Japanese ParticipantsExperimental Treatment1 Intervention

Participants will receive ABBV-552 once a week for 21 Days.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ABBV-552

2023

Completed Phase 1

~20

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor

958 Previous Clinical Trials

502,366 Total Patients Enrolled

ABBVIE INC.Study DirectorAbbVie

397 Previous Clinical Trials

147,080 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the arm of this study involving healthy Japanese individuals been approved by the FDA?

"The safety of Arm 1: Healthy Japanese Participants is estimated at a score of 1 due to the lack of data regarding efficacy and safety, as this is an experimental Phase one trial."

Answered by AI

Who qualifies for enrollment in this medical experiment?

"Qualifying individuals should be healthy adults in the 18 to 55 age range, and this study aims to recruit roughly 18 participants."

Answered by AI

Are participants at least 85 years of age eligible for this exploration?

"Eligible participants in this medical study must be between 18 and 55 years old."

Answered by AI

Does this research currently have open enrollment?

"This clinical trial, which was initially shared on January 17th 2023 and recently updated on the 13th of this month, is actively looking for participants. This information can be found on clinicaltrials.gov."

Answered by AI

What is the total enrollment of this research project?

"That is correct. According to the clinicaltrials.gov platform, this medical investigation has been recruiting since January 17th 2023 and was last updated on January 13th 2023. Currently, 18 participants are needed across two distinct research centres."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

2023. "A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05686980.